Patients Pharmacy First: Why technology is necessary for safeguarding... The challenges facing UK healthcare are abundantly clear.
News Could a Novo error set up early GLP-1 generics in Canada? Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
